
TCM Group A/S: Kvartalsrapport Q1 2023
SELSKABSMEDDELELSE
Nr. 166/2023
Tvis, 16. maj 2023
Kvartalsrapport Q1 2023 (1. januar – 31. marts)
(Tallene i parentes henviser til den tilsvarende periode i 2022)
Omsætningen udviste stor stabilitet i et udfordret marked, men indtjeningen var negativt påvirket af mix effekter, højere driftsomkostninger og omkostninger til forhandler omstrukturering. Omsætningsforventning fastholdes, mens EBIT-forventning justeres.
CEO Torben Paulin:
"Vi er tilfredse med at salget udviste stor stabilitet i 1. kvartal på trods af udfordrende markedsforhold. Forbrugerefterspørgslen fortsatte den svage tendens fra andet halvår af 2022, men på grund af TCM's stærke position i B2B og salgsprisstigningerne gennemført i 2022, var salget stort set uændret faldende med kun 3% i 1. kvartal sammenlignet med 1. kvartal sidste år.
Vores flagskibs brand, Svane Køkkenet, forsvarede med succes sin markedsposition i Danmark med uændret salg i et generelt negativt marked, mens både private labelforretningen og salget i e-handelskanalen viste gode vækstrater. I Norge fortsatte den stærke udvikling med en salgsvækst på 4,4% målt i lokal valuta.
På trods af de salgsprisstigninger der er gennemført de seneste 12 måneder, var bruttomarginen i kvartalet negativt påvirket salgsmix effekter fra en stigende andel af B2B-salg med lavere margin, sammenlignet med 1. kvartal sidste år. Derudover udvandede stigende råvarepriser og stigninger i prisen på komponenter også marginen. Samlet steg de direkte inputomkostninger med mere end 10% sammenlignet med 1. kvartal sidste år. Desuden påvirkede væsentligt højere energi- og fragtomkostninger bruttoresultatet negativt. Endvidere blev salgs- og administrations omkostninger i kvartalet negativt påvirket af DKK 3,0 millioner i omkostninger til omstruktureringer af en række butikker.
I løbet af 1. kvartal af 2023, og i lighed med de to foregående kvartaler, fortsatte TCM omstruktureringen af organisationen for at afspejle udviklingen i forbrugerefterspørgslen. Således blev arbejdsstyrken i både produktions- og stabsfunktioner reduceret med i alt 35 årsværk i kvartalet. Reduktionerne, som forventes at have fuld effekt fra 3. kvartal 2023, medførte en engangsomkostning på DKK 1,7 millioner.
Vi fastholder vores forventning til helårsomsætningen, men vi justerer forventningen til justeret EBIT: Helårs omsætningen forventes stadig i intervallet DKK 950 – 1.050 millioner (uændret), mens vi nu forventer et justeret EBIT i intervallet DKK 60-90 millioner (tidligere: DKK 70-100 millioner).”
Finansielle nøgletal 1. kvartal 2023
- Omsætning DKK 273,6 millioner (DKK 281,4 millioner) svarende til et omsætningsfald på 2,8%.
- Justeret EBITDA DKK 17,9 millioner (DKK 30,3 millioner). Justeret EBITDA margin var 6,6% (10,8%).
- Justeret EBIT faldt med DKK 12,9 millioner til DKK 13,1 millioner (DKK 26,0 millioner). Justeret EBIT-margin var 4,8% (9,3%).
- Engangsposter havde en samlet negativ indvirkning på DKK 1,7 millioner (DKK 5,4 million). Engangsposter inkluderede omkostninger relateret til organisations omstrukturering.
- EBIT faldt DKK 9,2 millioner til DKK 11,4 millioner (DKK 20,6 millioner) svarende til en EBIT-margin på 4,1% (7,3%).
- Periodens resultat faldt med DKK 11,2 millioner til DKK 5,4 millioner (DKK 16,6 millioner).
- Frie pengestrømme var DKK -35,0 millioner (DKK -32,9 millioner).
- Cash conversion ratio var 68,2% (60,5%).
- Finansielle forventninger for helåret er en omsætning i niveauet DKK 950-1.050 millioner og justeret EBIT i niveauet DKK 60-90 millioner.
For yderligere information:
Torben Paulin, CEO TCM Group A/S, +45 21 21 04 64
Thomas Hjannung, CFO TCM Group A/S, +45 97 43 52 00
IR Kontakt: ir@tcmgroup.dk
Om TCM Group
TCM Group er Skandinaviens tredjestørste producent af køkkener, badeværelses- og opbevaringsmøbler. Produkterne er designet og produceret i Danmark og er rodfæstet i en stolt tradition for kvalitet og solidt håndværk. TCM Group fører en multibrand-strategi, hvor Svane Køkkenet er det primære brand, mens de øvrige brands er Tvis Køkken og Nettoline. Samlet dækker disse brands hele prisspektret, og de sælges gennem ca. 140 forhandlere i Danmark og resten af Skandinavien. TCM Group sælger desuden køkkener som private label gennem byggemarkedskæder i Danmark og uafhængige køkkenforretninger i Norge. TCM Group er leverandør til den 45% ejede e-commerce køkkenvirksomhed Celebert, som opererer gennem de forskellige brands kitchn.dk, billigskabe.dk, Celebert og Just Wood. Yderligere oplysninger fås på hjemmesiden www.tcmgroup.dk.
Vedhæftede filer
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are